canada life equity release

Leveljump Healthcare Corp. Announces $3.2 Million Term Loan Commitment from TD Canada Trust

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that it has secured a term loan commitment from TD Canada Trust for $3.2 million for the purpose of closing the Company's previously announced acquisition of three Ontario Diagnostic Imaging Clinics (Press release September 28, 2021).

Combined with the Company's cash on hand, the term loan will allow the Company to close the Ontario Diagnostic Imaging Clinics acquisition.

The loan facility will be a $3.2 million term loan, amortized over 10 years and the expected interest rate is to be less than 4%. The loan calls for monthly payments of principal and interest and an annual payment of 25% of excess EBITDA towards principal.

Additionally, TD Canada Trust is supplying the company with a $150,000 operating line of credit at Prime +1.5%.

"We are very excited to have TD Canada Trust act as our partner in this acquisition and we look forward to being able to present them with our additional acquisitions in the near future with a goal to expanding our relationship and building JUMP," said Mitchell Geisler, Chief Executive Officer of the Company.

Closing of the loan is subject to a number of diligence items and covenants as requested by the bank and the Company believes these will all be met prior to closing the acquisition.

About Leveljump Healthcare

LevelJump Healthcare Corp., (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology. The Company's subsidiary, CTS, provides off-site radiology readings for hospital emergency rooms and is a leader in the teleradiology space in Ontario. As part of our growth strategy, we are acquiring healthcare companies that have strong revenue and cash flow, with room for organic growth.

ON BEHALF OF THE BOARD OF DIRECTORS OF
LevelJump Healthcare Corp.

Mitchell Geisler, Chief Executive Officer
info@leveljumphealthcare.com
(833) 840-2020

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/105118

News Provided by Newsfile via QuoteMedia

The Conversation (0)

Medtronic announces CMS national coverage analysis for Symplicity Spyral Renal Denervation System

  • National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure
  • Milestone is supported by large public health need and robust, long-term data from the SPYRAL-HTN global clinical program

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension. This national coverage analysis was initiated by CMS in response to Medtronic's request to support Medicare beneficiary access to the Symplicity™ Spyral renal denervation (RDN) system, used in the Symplicity blood pressure procedure.

"Hypertension is a global health epidemic that impacts a wide variety of patients," said Jason Weidman , senior vice president and president of the Coronary and Renal Denervation business within the Cardiovascular Portfolio at Medtronic. "As the leader in developing a minimally invasive treatment option for hypertension, Medtronic has been closely engaged with CMS to establish a national coverage pathway for Symplicity Spyral. We appreciate CMS' efforts in creating new pathways to expedite access to breakthrough technologies like Symplicity Spyral and look forward to our continued partnership in developing a national coverage policy."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic announces CMS national coverage analysis for Symplicity Spyral Renal Denervation System

  • National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure
  • Milestone is supported by large public health need and robust, long-term data from the SPYRAL-HTN global clinical program

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension. This national coverage analysis was initiated by CMS in response to Medtronic's request to support Medicare beneficiary access to the Symplicity™ Spyral renal denervation (RDN) system, used in the Symplicity blood pressure procedure.

"Hypertension is a global health epidemic that impacts a wide variety of patients," said Jason Weidman , senior vice president and president of the Coronary and Renal Denervation business within the Cardiovascular Portfolio at Medtronic. "As the leader in developing a minimally invasive treatment option for hypertension, Medtronic has been closely engaged with CMS to establish a national coverage pathway for Symplicity Spyral. We appreciate CMS' efforts in creating new pathways to expedite access to breakthrough technologies like Symplicity Spyral and look forward to our continued partnership in developing a national coverage policy."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic achieves CE Mark approval for BrainSense Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson's through innovative brain-computer interface technology

European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced today CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI), having achieved the standards required by the EU Medical Device Regulation (MDR). In addition, the first programming was completed today, performed by Martijn Beudel, MD, PhD, neurologist and associate professor, Department of Neurology, Amsterdam University Medical Center. This landmark approval and first-in- Europe patient programming demonstrate significant advancements in personalized DBS therapy for people with Parkinson's in Europe including the UK.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic achieves CE Mark approval for BrainSense Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson's through innovative brain-computer interface technology

European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced today CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI), having achieved the standards required by the EU Medical Device Regulation (MDR). In addition, the first programming was completed today, performed by Martijn Beudel, MD, PhD, neurologist and associate professor, Department of Neurology, Amsterdam University Medical Center. This landmark approval and first-in- Europe patient programming demonstrate significant advancements in personalized DBS therapy for people with Parkinson's in Europe including the UK.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Study

UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discovery

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Study

UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discovery

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×